Aixiao Xu, Ning Zhang, Ji Cao, Hong Zhu, Bo Yang, Qiaojun He, Xuejing Shao, Meidan Ying
Abstract
["Retinoic acid (RA) is a well-known differentiation inducer that exerts its effects by binding to nuclear RA receptors. Retinoic acid receptor \u03b1 (RAR\u03b1), as an important nuclear RA receptor, is activated upon RA binding and facilitates the transcription of target genes related to differentiation, which ultimately initiates cell differentiation. Previous studies have found that the transcriptional activity of RAR\u03b1 is regulated by various post-translational modifications, which influence its DNA binding efficiency, transactivation ability and even lead to degradation. Post-translational modifications of RAR\u03b1, as a consequence, play an important role in the RA-induced differentiation process. Therefore, in this review, we focus on recent advances in the understanding of how these modifications affect the activity of RAR\u03b1 as well as strategies to increase the differentiation effect of RA treatment in cancer cells based on RAR\u03b1 modifications, which may promote the development of novel effective differentiation therapies for cancer treatment.",{"copyright":"Copyright \u00a9 2019 Elsevier Inc. All rights reserved."}]
Address:
Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.; Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University, Zhejiang University, Hangzhou, China.; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Electronic address:
[email protected].; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Electronic address:
[email protected].